You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hu14.18-IL2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Madison (hu14.18-IL2, Radiation Therapy, Nivolumab)

Suspended
  • Melanoma
  • hu14.18-IL2
  • +3 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Jan 3, 2022

Melanoma Trial in Madison (hu14.18-IL2)

Completed
Has Results
  • Melanoma
  • hu14.18-IL2
  • Madison, Wisconsin
    University of Wisconsin Hospitals and Clinics
Nov 13, 2019

Melanoma (Skin) Trial in Madison (hu14.18-IL2 fusion protein)

Completed
  • Melanoma (Skin)
  • hu14.18-IL2 fusion protein
  • Madison, Wisconsin
    University of Wisconsin Paul P. Carbone Comprehensive Cancer Cen
Nov 15, 2019

Metastatic Solid Tumor Trial ([18F]AlF-RESCA-IL2 PET scan)

Not yet recruiting
  • Metastatic Solid Tumor
  • [18F]AlF-RESCA-IL2 PET scan
  • (no location specified)
Jul 20, 2022

Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

Terminated
  • Neuroblastoma
  • antibody ch14.18
  • +4 more
  • Cologne, Germany
    University of Cologne
Nov 3, 2022

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2023

Smallpox, Monkeypox, Cowpox Trial in Novosibirsk (NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally,

Completed
  • Smallpox
  • +3 more
  • NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
  • +5 more
  • Novosibirsk, Koltsovo, Novosibirsk Region, Russian Federation
    Federal State Budgetary Healthcare Institution - Medical and San
Jul 27, 2023

Systemic Lupus Erythematosus Trial in Beijing (Telitacicept, Interleukin-2)

Recruiting
  • Systemic Lupus Erythematosus
  • Beijing, Beijing, China
    Department of Rheumatology and Immunology, Peking University Peo
Apr 26, 2022

Healthy Volunteers Trial in Nottingham ([14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule)

Completed
Has Results
  • Healthy Volunteers
  • Nottingham, United Kingdom
    Quotient Sciences
Jan 17, 2023

COVID-19 Trial in Chengdu (LYB002V14, LYB002V14A, LYB002CA)

Active, not recruiting
  • COVID-19
  • LYB002V14
  • +2 more
  • Chengdu, Sichuan, China
    Affiliated Hospital of North Sichuan MedicalCollege
Jun 29, 2023

Contribution of Inflammation and Neuronal Integrity Markers in

Recruiting
  • Conversion Disorder
  • blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)
  • Nîmes, Choisir Une Région, France
    Ismael CONEJERO
Apr 15, 2022

Pemphigus Vulgaris, Pemphigus Foliaceus Trial in Worldwide (efgartigimod PH20 SC, prednisone)

Recruiting
  • Pemphigus Vulgaris
  • Pemphigus Foliaceus
  • Birmingham, Alabama
  • +120 more
Dec 22, 2022

Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in United States

Active, not recruiting
Has Results
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • +6 more
  • Los Angeles, California
  • +3 more
Nov 16, 2022

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)

Active, not recruiting
  • Malignant Neoplasm
  • aldesleukin
  • +7 more
  • Los Angeles, California
    University of California at Los Angeles (UCLA )
Dec 1, 2022

Recurrent Neuroblastoma Trial in Canada, United States (biological, drug, other)

Completed
Has Results
  • Recurrent Neuroblastoma
  • hu14.18-IL2 fusion protein
  • +3 more
  • Birmingham, Alabama
  • +75 more
Oct 4, 2019

Ganglioneuroblastoma, High Risk Neuroblastoma Trial in Australia, New Zealand, United States (procedure, drug, biological,

Active, not recruiting
  • Ganglioneuroblastoma
  • High Risk Neuroblastoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +14 more
  • Los Angeles, California
  • +9 more
Sep 1, 2022

Bullous Pemphigoid Trial in Worldwide (biological, other, drug)

Recruiting
  • Bullous Pemphigoid
  • efgartigimod PH20 SC
  • +2 more
  • Fountain Valley, California
  • +24 more
Jul 27, 2022

Subarachnoid Hemorrhage Trial in United Kingdom (IL-1Ra, IL-1Ra Placebo)

Recruiting
  • Subarachnoid Hemorrhage
  • Plymouth, Devon, United Kingdom
  • +11 more
May 16, 2022

High Risk Neuroblastoma Trial in United States (biological, other, drug)

Completed
Has Results
  • High Risk Neuroblastoma
  • Aldesleukin
  • +4 more
  • Loma Linda, California
  • +31 more
Jul 30, 2021

COVID-19 Trial in Nanjing (Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14,

Recruiting
  • COVID-19
  • Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
  • +7 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022

Periodontitis, Cigarette Smoking Trial (Non-surgical periodontal therapy: motivation and instruction in oral hygiene,

Completed
  • Periodontitis
  • Cigarette Smoking
  • Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).
  • (no location specified)
Nov 2, 2021

Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

Recruiting
  • Neuroblastoma
  • Madison, Wisconsin
  • +2 more
Mar 28, 2022

Atopic Dermatitis Trial in Canada, United States (Abrocitinib)

Recruiting
  • Atopic Dermatitis
  • Fountain Valley, California
  • +8 more
Jan 25, 2023